Literature DB >> 12427625

The effect of hydroxyurea on vasculopathy in a child with sickle cell disease.

Kathleen J Helton1, Winfred C Wang, Lynn W Wynn, Raja B Khan, R Grant Steen.   

Abstract

We report serial CNS findings in a girl with sickle cell disease and stroke. Religious considerations precluded transfusion and bone marrow transplantation; therefore, she received single-agent hydroxyurea therapy for almost 6 years. MR angiography showed that vascular patency improved, although diffuse cerebral atrophy slowly worsened. Hydroxyurea can be effective in treating vasculopathy, but it might not prevent the progression of parenchymal damage in advanced disease.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12427625      PMCID： PMC8185829     

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN： 0195-6108            Impact factor:   3.825


  16 in total

Review 1.  Management of sickle cell disease.

Authors:  M H Steinberg
Journal:  N Engl J Med       Date:  1999-04-01       Impact factor: 91.245

2.  Valproic acid and augmentation of fetal hemoglobin in individuals with and without sickle cell disease.

Authors:  R Selby; E Nisbet-Brown; R K Basran; L Chang; N F Olivieri
Journal:  Blood       Date:  1997-07-15       Impact factor: 22.113

3.  Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Multicenter Study of Hydroxyurea.

Authors:  M H Steinberg; Z H Lu; F B Barton; M L Terrin; S Charache; G J Dover
Journal:  Blood       Date:  1997-02-01       Impact factor: 22.113

4.  Hydroxyurea as an alternative to blood transfusions for the prevention of recurrent stroke in children with sickle cell disease.

Authors:  R E Ware; S A Zimmerman; W H Schultz
Journal:  Blood       Date:  1999-11-01       Impact factor: 22.113

5.  Improved cerebrovascular patency following therapy in patients with sickle cell disease: initial results in 4 patients who received HLA-identical hematopoietic stem cell allografts.

Authors:  R G Steen; K J Helton; E M Horwitz; E Benaim; S Thompson; L C Bowman; R Krance; W C Wang; J M Cunningham
Journal:  Ann Neurol       Date:  2001-02       Impact factor: 10.422

6.  Cerebrovascular accidents in sickle cell disease: rates and risk factors.

Authors:  K Ohene-Frempong; S J Weiner; L A Sleeper; S T Miller; S Embury; J W Moohr; D L Wethers; C H Pegelow; F M Gill
Journal:  Blood       Date:  1998-01-01       Impact factor: 22.113

7.  Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group.

Authors:  T R Kinney; R W Helms; E E O'Branski; K Ohene-Frempong; W Wang; C Daeschner; E Vichinsky; R Redding-Lallinger; B Gee; O S Platt; R E Ware
Journal:  Blood       Date:  1999-09-01       Impact factor: 22.113

8.  Effect of transfusion therapy on arteriographic abnormalities and on recurrence of stroke in sickle cell disease.

Authors:  M O Russell; H I Goldberg; A Hodson; H C Kim; J Halus; M Reivich; E Schwartz
Journal:  Blood       Date:  1984-01       Impact factor: 22.113

9.  The spectrum of brain MR abnormalities in sickle-cell disease: a report from the Cooperative Study of Sickle Cell Disease.

Authors:  F G Moser; S T Miller; J A Bello; C H Pegelow; R A Zimmerman; W C Wang; K Ohene-Frempong; A Schwartz; E P Vichinsky; D Gallagher; T R Kinney
Journal:  AJNR Am J Neuroradiol       Date:  1996-05       Impact factor: 3.825

10.  Cerebral infarction in sickle cell anemia: mechanism based on CT and MRI.

Authors:  R J Adams; F T Nichols; V McKie; K McKie; P Milner; T E Gammal
Journal:  Neurology       Date:  1988-07       Impact factor: 9.910
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.